君實生物(01877.HK)2020年營收預增105.14%
格隆匯 1 月 29日丨君實生物(01877.HK)發佈2020年年度業績預吿,公司預計2020年年度實現營業收入159,000.00萬元左右(人民幣,下同),與上年同期相比增長81,491.08萬元左右,同比增長105.14%左右。預計2020年年度研發費用為182,400.00萬元左右,與上年同期相比增長92.79%左右。
報吿期內,公司營業收入大幅提升,已基本可覆蓋公司除研發投入之外的產品推廣及日常運營等支出。2020年度,公司不斷加強核心產品特瑞普利單抗注射液(商品名:拓益®)的市場推廣力度,擴充一線市場推廣人員數量,加大團隊建設的投入,快速提升產品的醫院覆蓋率,特瑞普利單抗注射液的銷售收入逐步增長。同時,公司的研發成果轉換能力逐步顯現,報吿期內新增對外許可收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.